
USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$139.09M
Market Cap
-
P/E Ratio
-1.57
EPS
$7.34
52 Week High
$1.38
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$158M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $13M |
| Capital Expenditures | $576K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $27K |
| Cashflow From Financing | $123M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$232M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Agenus Inc. is a leading clinical-stage immuno-oncology company focused on discovering and developing innovative immunotherapy treatments aimed at enhancing the body’s immune response against cancer. Headquartered in Lexington, Massachusetts, Agenus is at the forefront of research in checkpoint inhibitors and other immunotherapies, positioning itself as a key player in the rapidly evolving oncology landscape. With a robust pipeline of therapeutics and a commitment to advancing patient care, Agenus is poised to capitalize on the increasing demand for effective cancer treatments globally.